Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Clin-Experts | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
The sleep apnea-hypopnea syndrome is characterized by the occurrence, during sleep, of abnormally frequent episodes of interruption of ventilation (apnea), or significant reduction in ventilation (hypopnea).
The main symptoms of sleep apnea-hypopnea syndrome are daytime sleepiness (caused by the fragmentation and breakdown of sleep) and nocturnal snoring; possibly accompanied by the following symptoms: non-restorative sleep, difficulty concentrating, nocturia, cognitive disorders, libido disorders.
The consequences of sleep apnea-hypopnea syndrome are multiple for the patient both in the short term and in the long term.
The short-term manifestations are as follows: daytime sleepiness, reduced alertness, difficulty driving (risk of road accidents), difficulty performing tasks (risk of accidents at work), memory and concentration problems , learning difficulties (especially in children), mood disorders. In the end, there is an alteration in the quality of life of the patient.
Sleep apnea-hypopnea syndrome also has long-term consequences: a link between sleep apnea-hypopnea syndrome and cardiovascular morbidity and mortality has been explored by several cohort studies.
Nasal ventilation by continuous positive airway pressure is considered the reference treatment for sleep apnea-hypopnea syndrome. The use of nasal ventilation by continuous positive airway pressure, compared to no treatment, is not associated with a reduced risk of cardiovascular outcomes or death in patients with sleep apnea according to a recent meta-analysis.
Mandibular advancement devices are an alternative treatment for nasal ventilation by continuous positive airway pressure. The acceptability of its treatments, whether nasal ventilation by continuous positive airway pressure or mandibular advancement devices, is not very good and some patients do not start treatment or abandon it because of the constraints related to these treatments. There is therefore a need to find other treatments.
The overnight rostral fluid displacement from the legs, related to prolonged sitting can generate edema in the neck, more precisely in the upper airways, and therefore obstructive respiratory dysfunctions responsible for sleep apnea-hypopnea syndrome. Correlations between nocturnal fluid shifts and the number of apneas/hypopneas have been demonstrated Previous studies has shown a reduction in the apnea-hypopnea index by the daytime preventive wearing of medical compression, which can reduce the extent of leg edema and the displacement of nocturnal fluids.
The aim of the present study is to show that daytime wearing of medical compression developed specifically to optimize its effect in this indication for 28 days versus not wearing it reduces the number of apneas/hypopneas in patients with sleep apnea-hypopnea syndrome.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Compression stockings - No Compression | Experimental | The patient will wear specific compression stockings in the first phase, and no compression in the second phase of the study |
|
| No Compression - Compression stockings | Experimental | The patient won't wear anything in the first phase, and specific compression stockings in the second phase of the study |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Wearing of specific compression stockings | Device | The patient will wear specific compression stockings prevent the accumulation of fluids during the day in the lower part of the body and thus limiting the nocturnal drainage effect from the lower part of the body to the upper part of the body |
| Measure | Description | Time Frame |
|---|---|---|
| Change in the number of apneas/hypopneas | 28 days |
| Measure | Description | Time Frame |
|---|---|---|
| Proportion of patients with a 50% reduction in the apnea-hypopnea index | 28 days | |
| Proportion of patients with an apnea-hypopnea index < 30/hour | 28 days | |
| Proportion of patients with an apnea-hypopnea index < 15/hour |
Not provided
Inclusion Criteria:
patient with moderate to severe sleep apnea-hypopnea syndrome confirmed by polysomnography dating less than 3 months with an index of apneas/hypopneas ≥ 15 apneas-hypopneas/h
having been previously treated with nasal ventilation by continuous positive airway pressure and mandibular orthosis and having stopped treatment for at least 10 days, regardless of the duration of use of these two treatments
or never treated for their sleep apnea-hypopnea syndrome satisfying the following 3 criteria
stable weight (5% variation of the weight at the time of the polysomnography done within 3 months)
patient without varicose veins, without trophic disorder that could suggest moderate to severe superficial or deep venous insufficiency (dermatitis, hypodermatitis, active or healed ulcer)
sedentary patient (patient seated more than 8 h/d
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Service des Pathologies du Sommeil Bâtiment EOLE GH Pitié-Salpêtrière | Paris | 75013 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
| 28 days |
| Proportion of patients with a 50% reduction in the apnea-hypopnea index and an apnea-hypopnea index < 15/hour | 28 days |
| Change in sleep habits and characteristics | Change in sleep habits and characteristics will be evaluated with an ad hoc questionnaire | 28 days |
| Change in sleepiness | Sleepiness will be assessed by Epworth scale | 28 days |
| Change in clinical signs of rostral displacement of fluids | 28 days |
| Tolerance overall judgment and questionnaire and adverse events) | overall judgment by the patient and questionnaire filled by the investigator | 28 days (only during the phase with the wearing of compression stockings |
| ID | Term |
|---|---|
| D012891 | Sleep Apnea Syndromes |
| D020181 | Sleep Apnea, Obstructive |
| ID | Term |
|---|---|
| D001049 | Apnea |
| D012120 | Respiration Disorders |
| D012140 | Respiratory Tract Diseases |
| D020919 | Sleep Disorders, Intrinsic |
| D020920 | Dyssomnias |
| D012893 | Sleep Wake Disorders |
| D009422 | Nervous System Diseases |
Not provided
Not provided